Kenilworth-based Merck announced that the company is halting the development of its candidate vaccines COVID-19, V590 and V591.
The decision follows the company’s review of the results of Phase 1 clinical trials for vaccines.
In studies, both V590 and V591 were generally well tolerated, but immune responses were lower than those seen after natural infection and those reported for other SARS-CoV-2 / COVID-19 vaccines.
The company now plans to focus its COVID-19 research strategy and production capabilities on advancing two therapeutic candidates, MK-4482 and MK-7110.
For more information click here.